An Alzheimer’s rejection; Our #JPM23 dispatches; Count Moderna in for RSV; Biotech layoffs persist; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
We began the week with an American holiday and now end with an East Asian one. Happy Lunar New Year to all who celebrate!
An Alzheimer’s rejection
Just days after waving through Biogen and Eisai’s Leqembi, the FDA squashed accelerated hopes for Eli Lilly’s Alzheimer’s drug, asking for more data. Lilly said regulators denied the accelerated approval for its anti-amyloid antibody, donanemab, “based on limited number of patients with 12-month drug exposure data” in the submission. The company had been planning to file for full approval once it reports Phase III data later this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.